OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Rating of "Buy" by Brokerages

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) has earned an average rating of "Buy" from the five research firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $2.75.

Several research analysts have issued reports on OPK shares. LADENBURG THALM/SH SH upgraded shares of OPKO Health to a "strong-buy" rating in a report on Tuesday. Barrington Research reiterated an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a report on Thursday, May 1st. HC Wainwright reiterated a "buy" rating and set a $3.00 target price on shares of OPKO Health in a report on Monday, April 7th. JPMorgan Chase & Co. started coverage on shares of OPKO Health in a report on Friday, April 25th. They set a "neutral" rating on the stock. Finally, Wall Street Zen cut shares of OPKO Health from a "hold" rating to a "sell" rating in a report on Monday, May 5th.

Institutional Investors Weigh In On OPKO Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. grew its stake in OPKO Health by 4.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,001,214 shares of the biotechnology company's stock valued at $6,642,000 after acquiring an additional 161,394 shares during the period. Strs Ohio acquired a new stake in OPKO Health in the 1st quarter valued at $53,000. Caxton Associates LLP acquired a new stake in OPKO Health in the 1st quarter valued at $130,000. Voleon Capital Management LP acquired a new stake in OPKO Health in the 1st quarter valued at $45,000. Finally, Millennium Management LLC boosted its stake in OPKO Health by 39.2% during the 1st quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company's stock worth $10,602,000 after purchasing an additional 1,798,385 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company's stock.

OPKO Health Trading Up 1.5%

Shares of OPK opened at $1.38 on Thursday. OPKO Health has a twelve month low of $1.21 and a twelve month high of $2.04. The company has a market cap of $1.09 billion, a P/E ratio of -19.71 and a beta of 1.34. The company has a current ratio of 2.49, a quick ratio of 2.28 and a debt-to-equity ratio of 0.25. The company's fifty day simple moving average is $1.32 and its 200-day simple moving average is $1.49.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.03). The company had revenue of $149.90 million during the quarter, compared to the consensus estimate of $163.13 million. OPKO Health had a negative return on equity of 2.85% and a negative net margin of 5.66%. The company's revenue for the quarter was down 13.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.12) earnings per share. As a group, analysts expect that OPKO Health will post -0.25 EPS for the current year.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.